finafloxacin,
Xtoro,
Finafloxacin,
209342-40-5,
Xtoro,
UNII-D26OSN9Q4R,
D26OSN9Q4R,
CHEBI:85176,
Finafloxacin (INN),
Finafloxacin [INN],
8-cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
Xtoro;7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid,
gastrochinolon,
gastroquinolone,
8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
Xtoro (TN),
QCR-30,
SCHEMBL1002869,
CHEMBL1908370,
DTXSID10175096,
FYMHQCNFKNMJAV-HOTGVXAUSA-N,
BCP23882,
ZINC3985346,
CS-5557,
DB09047,
SB17124,
BAY35-3377,finafloxacin hydrochloride,
AC-29291,
HY-13451,
D10575,
(-)-8-Cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-4-oxo-1,
(-)-8-Cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-,
3-Quinolinecarboxylic acid,8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-,
7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid,hydrochloride,
8-cyano-1-cyclopropyl-6-fluoro-7-((1S,6S)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid,
finafloxacin HCl,
Finafloxacin hydrochloride,
D01IXD,
BAY35-3377,
CID11567473,
CID 11567473,
Finafloxacin (iv, bacterial infection), MerLion/Alcon,
Finafloxacin (oral, bacterial infection), MerLion/Alcon,
Antibacterial (Helicobacter pylori infection/ bacterial urinary tract infection), Combinature,
209342-41-6,